Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive ...

Brisbane-based Vaxxas has appointed David Peacock to lead the push to bring its vaccine patch technology to market.

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

A recent study highlights how DNA microarray technology enables high-throughput gene analysis, supporting variation detection, expression profiling, and clinical research. By refining probe design and ...

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

As genetic analysis expands to serve everything from population-scale studies to precision-driven clinical decisions, laboratories are under growing pressure to move faster while managing increasingly ...

InDevR, a Boulder-based biotechnology company that develops advanced life science instrumentation and assays for analysis of viruses and other microorganisms, announced today the launch revolutionary ...

The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...